Human T cell lymphotropic virus type I does not increase human immunodeficiency virus viral load in vivo

J Infect Dis. 1997 Feb;175(2):438-40. doi: 10.1093/infdis/175.2.438.

Abstract

Human T lymphotropic virus type I (HTLV-I) can increase human immunodeficiency virus (HIV) replication in vitro, and several studies suggest that HTLV-I accelerates the progression of HIV infection. To determine whether HTLV-I enhances HIV replication in vivo, a case-control study was done of serum HIV viral load, using polymerase chain reaction, in 23 subjects with HTLV-I/HIV coinfection and 92 control subjects with HIV single infection. The geometric mean serum RNA level was 11,482 copies/mL in the coinfected group and 13,804 in the single-infection group (P = .57), a result that did not change after adjustment for zidovudine use and CD4 cell count. Among subjects with advanced HIV infection, there was a trend toward higher viral load among singly infected subjects. HTLV-I did not appear to increase HIV plasma RNA levels in subjects with coinfection. These results do not provide a biologic basis for the hypothesis that HTLV-I accelerates the course of HIV infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use
  • CD4 Lymphocyte Count
  • Case-Control Studies
  • HIV / genetics
  • HIV / growth & development*
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • HIV Infections / epidemiology
  • HTLV-I Infections / complications*
  • HTLV-I Infections / epidemiology
  • Humans
  • Polymerase Chain Reaction
  • RNA, Viral / analysis
  • RNA, Viral / blood
  • Viral Load*
  • Zidovudine / therapeutic use

Substances

  • Anti-HIV Agents
  • RNA, Viral
  • Zidovudine